Who is affected by this change?

This affects Independence Blue Cross OB-GYN, Family Medicine providers on Commercial plans.

When does this change take effect?

This change is effective Apr 2, 2025.

Back to dashboard

CommercialCoverageMedium impact

06.02.04d, Fetal Fibronectin Enzyme (fFN) Immunoassay

Independence Blue Cross·OB-GYN, Family Medicine·Medical Policy

Effective date

Apr 2, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Independence Blue Cross has reissued policy 06.02.04d regarding Fetal Fibronectin Enzyme (fFN) Immunoassay testing with an effective date of April 2, 2025. This is a policy reissuance for commercial plans, though specific changes are not detailed in the summary provided.

Action Required

Action needed

By April 2, 2025: Billing team should review the complete updated policy at the provided URL to identify any changes to coverage criteria, prior authorization requirements, or billing guidelines for fetal fibronectin testing. Update billing procedures accordingly based on the full policy content.

Related policy hubs

Independence Blue Cross policies OB-GYN Family Medicine